Aponvie FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 28, 2022.
FDA Approved: Yes (First approved September 16, 2022)
Brand name: Aponvie
Generic name: aprepitant
Dosage form: Injection
Previous Name: HTX-019
Company: Heron Therapeutics, Inc.
Treatment for: Nausea/Vomiting, Postoperative
Aponvie (aprepitant) is an intravenous formulation of the approved antiemetic aprepitant indicated for the prevention of postoperative nausea and vomiting (PONV).
- Aprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist previously approved for the prevention of chemotherapy-induced nausea and vomiting (CINV) in oral formulations (Emend) and an injectable emulsion (Cinvanti). The Aponvie injectable emulsion formulation of aprepitant for the prevention of PONV is identical to the Cinvanti formulation for the prevention of CINV.
- Aponvie is administered as a 30 second intravenous injection prior to induction of anesthesia.
- Warnings and precautions associated with Aponvie include hypersensitivity reactions, and drug interactions.
- Common adverse reactions include constipation, fatigue, and headache.
Development timeline for Aponvie
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
